PR Newswire Clinical TrialsOriginal article
Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
RegulatoryapprovedHBM7004Positive
AI Analysis
Summary
Harbour BioMed announced NMPA approval of its IND application for HBM7004, an antibody therapeutic candidate for the treatment of advanced solid tumors. The approval enables the company to initiate clinical development of the candidate in China.
Outcome Details
NMPA approval of IND application
Importance:6/10
Sentiment:
0.70
NMPAIND approvaloncologyantibody therapeuticsadvanced solid tumors
Read the original article
Published by PR Newswire Clinical Trials on August 18, 2026 9:02 AM